Xpert MTB/RIF and Xpert Ultra assays for pulmonary tuberculosis and rifampicin resistance in adults irrespective of signs or symptoms of pulmonary tuberculosis
Adrienne E. Shapiroa b c, Jennifer M. Rossa b c, Ian Schillerd e f, Mikashmi Kohlif g h, Nandini Dendukurie f i, Karen R Steingartj k l, David J. de L. Horneb m n
- aDivision of Allergy & Infectious Diseases, Global Health & Medicine
- bUniversity of Washington
- cSeattle USA
- dCentre for Outcomes Research
- eMcGill University Health Centre - Research Institute
- fMontreal Canada
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
Objectives This is a protocol for a Cochrane Review (diagnostic). The objectives are as follows: To determine the accuracy of Xpert MTB/RIF and Xpert Ultra for screening for tuberculosis in adults irrespective of signs or symptoms of pulmonary tuberculosis in the general population (i.e. low‐risk population). To determine the accuracy of Xpert MTB/RIF and Xpert Ultra for screening of pulmonary tuberculosis in adults in the following high‐risk groups. People living with HIV. Household contacts of people with tuberculosis. Patients residing in high‐tuberculosis‐burden settings attending primary health facilities. Homeless people. Miners. People with diabetes mellitus. People who abuse alcohol. Smokers. People residing in prisons. Healthcare workers. To determine the accuracy of Xpert MTB/RIF and Xpert Ultra for the detection of rifampicin resistance in the general population and in the high‐risk groups and settings described above. Secondary objectives To compare the accuracy of Xpert MTB/RIF and Xpert Ultra in the above high‐risk groups and settings. To investigate potential sources of heterogeneity in accuracy estimates, including the percentage of participants with tuberculosis symptoms, tuberculosis burden, tuberculosis/HIV burden, and MDR‐TB burden.
TL;DRThis is a protocol for a Cochrane Review (diagnostic) to determine the accuracy of Xpert MTB/RIF and Xpert Ultra for the detection of rifampicin resistance in the general population and in the high‐risk groups and settings. (Semantic Scholar)